  PI3KÎ´ ( idelalisib) and BTK ( ibrutinib) inhibitors have demonstrated significant clinical activity in chronic lymphocytic leukemia<disease> ( CLL) interfering with the cross-talk between CLL cells and the lymph node microenviroment , yet their mechanism of action remains to be fully elucidated. Here , we developed an